FDA gives tentative nod to Zydus Cadila for generic Rytary

Patients with Parkinson’s disease will soon have a new generic to treat their condition.

The Food and Drug Administration has given a tentative nod to Zydus Cadila for carbidopa and levodopa extended-release capsules in dosage strengths of 23.75 mg/95 mg, 36.25 mg/145 mg, 48.75 mg/195 mg, and 61.25 mg/245 mg.

The product is the generic of Impax Labs’ Rytary.

The medication is used to treat the symptoms of Parkinson's disease (such as shakiness, stiffness, difficulty moving) or Parkinson-like conditions.

The drug will be manufactured at the group’s formulation manufacturing facility at SEZ, Ahmedabad.